maternal death is greatest during labor and during the immediate postpartum period. The sudden increase in the pre-load immediately after delivery, due to auto transfusion from the uterus, may flood the central circulation, resulting in severe pulmonary edema. In addition, there continues to be auto transfusion of blood for 24-72 h after delivery.
Thus, the risk of pulmonary edema extends for several days after delivery. 2 Mortality in Class IV NYHA heart failure is high reaching up to 15-20%. [3] [4] [5] [6] [7] [8] [9] Despite the declining incidence of rheumatic heart disease, tertiary care hospitals in developing countries do treat a significant number of pregnant patients affected by rheumatic mitral valve disease. 9 In fact, rheumatic mitral stenosis forms 88% of the heart diseases complicating pregnancy in low to middle income group countries. 1, 3, 9 The option of surgical replacement of stenosed mitral valve causing decompensation during pregnancy is often being viewed as a challenge by the surgical team owing to unpredictable hemodynamics during and after cardio pulmonary bypass (CPB). Both maternal and utero placental circulation may have to tolerate the effects of CPB. The surgical techniques and overall CPB management have witnessed a tremendous change over years, but managing a successful maternal and fetal outcome in decompensated patients continue to remain a challenge for surgical and cardiac anesthesia teams. In patients who have compensated cardiac function, often surgery is deferred after delivery of the fetus, but in decompensated patients with failed medical treatment, this is not applicable. 4 A balloon mitral valvuloplasty procedure (BMV) is generally preferred over surgery in pregnancy in our institution as often the logistics and heart team decision is tilted towards a less invasive strategy as mentioned earlier.
Safety of BMV in pregnant patients has been published. [5] [6] [7] However severe sub valve disease and high Wilkin's score (>8-10) often results in sub optimal outcomes. [8] [9] [10] We sought to study the outcomes of BMV in pregnant patients with severe sub valve disease and who are severely ill with decompensated heart failure. The sub-valve disease was scored according to Wilkin's scoring. 10 These patients were being critically ill and required urgent intensive obstetric and anesthetic care in addition to the definitive valve procedure.
2 | METHODS
| Objectives of the study
To find the short and long term cardiac and obstetric outcomes following BMV in pregnant patients with MS and severe sub valve disease (Wilkins sub valve score three or more) and decompensated heart failure defined as (NYHA Class IV status/acute pulmonary edema/cardiogenic shock).
| Design
The study design was retrospective and prospective and was conducted at a tertiary care University level cardiac center in south India involving patients undergoing BMV from the year 2000-2012. The data were collected retrospectively from the patients' medical records, cardiac catheterization and BMV/surgical procedure reports.
| Study population
The majority of the long-term outcome data were obtained prospectively during patient follow-up visits. Approval to conduct the study was granted by the authors' institutional scientific and ethics committee. All results were based on the average of three measurements for patients in sinus rhythm and five measurements for patients in atrial fibrillation.
| Statistical methods
BMV was done according to the standard operating protocol.
The preference for local/general anesthesia was accorded by the anesthesia team. To reduce the maternal and fetal radiation, cine frame rate was kept at 7.5-frames/s. Abdominal lead gadget was The outcome variables included improvement in symptoms/ NYHA class, heart failure status, mortality and obstetric outcome (maternal and fetal). A successful obstetric outcome was defined as survival of mother and fetus with absence of major complications.
Occurrence of intra uterine death(IUD), pre term delivery and mode of delivery were recorded. Postnatal follow up and gradient details were collected from hospital records as well as prospectively during patient visits.
| Follow up
After delivery, patients were followed up monthly for the first year and yearly thereafter. Cardiac and non-cardiac mortality, re intervention (Re do BMV/mitral valve surgery) were documented. Survival curves were plotted for events after delivery comparing surgical and BMV groups. Table 2 . There was significant change in the measured mitral valve area (measured by polarimetry and pressure half time), mean mitral valve gradient and the mean left atrial pressure after BMV (P = 0.001). The mean ± SD Wilkin's score was 9.71 ± 2.1 (range 8-14) and the mean sub valve score was 3.3 ± 0.12 (3 to 4). Forty-one patients had high scores of >10. Sub group analysis of patients with high and low scores are given in Table 3 
| Immediate cardiac outcomes
The procedure was successful in 77 (80.2%) patients failed in 19 (19.8%). In 5 (5.2%) cases, acute severe MR occurred. There were 11 maternal deaths, 6 (31%) in failed and 5 (6%) in success group) during antenatal period after the procedure. The successful procedure could not salvage two patients who had concomitant HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet counts) and disseminated intra vascular coagulation. Two patients continued to be in cardiogenic shock despite successful BMV. They continued on mechanical support and sustained cardiac arrest. One patient had BMV on cardio pulmonary resuscitation, but BMV could not salvage the patient and she had on table death. There were no BMV related complications leading to death. There was one case of common femoral artery pseudo aneurysm, which was repaired surgically. The
Odds ratios for various clinical and echocardiographic variables predicting for morality and successful BMV are given in Tables 4 and 5, respectively. A high Wilkin's score, pulmonary artery hypertension and SpO 2 <90% had odds ratio of more than one in 
| Obstetric outcomes
Of the 72 patients who had procedural success and who survived pregnancy, 71 patients (98%) had a successful obstetric outcome.
Sixty-four patients had vaginal delivery and seven patients underwent caesarian section. There was one case of IUD. Six patients had pre term deliveries (four had emergency CS for fetal distress) with all babies surviving the neonatal period. In 19 patients who had failed BMV, 11
(57%) had successful obstetric outcome after surgical mitral valve replacement. There were two cases of IUD. Six patients underwent caesarian section. Three patients had pre term deliveries but all surviving the neonatal period.
| Valve surgery during pregnancy
Thirteen patients out of 19 (68% of failed) underwent surgical valve replacement. In five patients it was for acute severe valve regurgitation after BMV. There was one case of maternal mortality in this post surgical cohort due to poor post-operative recovery and severe right ventricular function.
| Follow up after delivery
Mean follow up period was 5.7 ± 0.2 years. There were overall four deaths in this period with worsening of heart failure. Of the 77 patients who had successful procedure seven patients (9%) had restenosis requiring re intervention at 5 years. In the 12 patients who were followed up after undergoing surgical mitral valve replacement, none 
| DISCUSSION
This study looked at the short and long-term outcomes in patients with severe mitral stenosis who were with advanced sub valve disease and with severe heart failure during their pregnancy. We had a group of patients who were severely ill clinically with pulmonary edema and/or hypoxemia and hypotension. Many of the patients were previously undiagnosed cases of rheumatic heart disease. This has resulted in many late presentations and advanced sub valve disease (the mean sub valve score was 3.3). These were a challenging substrate of patients to manage in clinical practice. The heart team decided for BMV (despite the sub valve thickening) rather than surgery in this cohort of patients due to the pregnancy status and decompensated clinical scenario as surgeons decided not to operate in many of this sicker patients. The heart team decision was to keep the surgical valve replacement as a bail out following a failed BMV.The study results showed advantages for BMV in improving clinical outcomes like reduction in cardiac mortality, improvement in obstetric outcomes and averting surgery.
The mortality rates were significantly different among success and failure (6% vs 31%). The outcomes in failed group was dismal with 31% mortality although a surgical bail out was performed in 13/19 failed patients. The obstetric outcomes followed a similar trend with 98% in successful BMV patients versus 57% in failed.
We had 11 maternal deaths during pregnancy and four late deaths during the 5-year follow up (15% mortality at 5 years). The antenatal deaths mainly occurred in failure groups (31% vs 5.4% in success). We observed an immediate success in about 80% cases.
This is lower than previously published series in pregnancy. 6, 9 We believe this is probably because of more patients with sub valve disease. Wilkin's score of more than 10 was predictive of mortality and a score of ≤10 was associated with a higher Odd's ratio for success similar to published literature. The absolute mean increment in the valve area was around 40% with 5% patients developing severe MR. As expected, the obstetric outcomes were significantly different in success and failed cases (92 vs 57%). This is probably because of premature uterine contractions and fetal distress settling in because of hemodynamic distress in heart failure and more patients died in the failed cohort in the antenatal period. In the 5 year follow up period, 90% patients remained free of events following a successful BMV as against 100% in 13 patients who survived after mitral valve replacement. The survival rates were similar after a successful intervention.
| Limitations of the study
The study had several limitations. It was a single center study.
Although all patients presented with NYHA IV symptoms and cardiorespiratory distress, no information was available on the pre pregnancy symptom status on these patients. The study was not powered to detect a meaningful survival advantage for BMV over surgery. More over lack of a surgical treatment arm as a control limited us from plotting a meaningful comparison between surgical treatment and the Kaplan Meir analysis was based on surgery that was offered as a bail out after failed BMV.
Furthermore, very few patients underwent surgery during the pregnancy period. The obstetric outcome is often a more useful in this type of study health index and this study does not indicate a valuable risk prediction model on this parameter.
| CONCLUSIONS
A successful BMV offers substantial improvement in cardiac and obstetric outcomes in pregnant patients with MS and decompensated heart failure even with severe sub valve disease. Immediate cardiac outcome after a failed BMV was poor with 31% mortality. The obstetric outcomes were again showing similar trend with more than 90% in success group having a good outcome. The incidence of acute severe MR was 5.2%. The long-term follow up after successful BMV was good with a re-intervention rate of 9% in this cohort and survival similar to following a valve replacement. ORCID
